A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

Purpose

TARGET-DERM is a 5-year, longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.

Conditions

  • Atopic Dermatitis
  • Alopecia
  • Hidradenitis Suppurativa
  • Vitiligo
  • Psoriasis

Eligibility

Eligible Ages
All ages
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • 1. Adults and children (all ages) with Atopic Dermatitis or other Immune-mediated Inflammatory Skin Conditions been prescribed any dermatologic treatment.
  • 2. Participant has plans for future visits at the site for continued management of IMISC.

Exclusion Criteria

  • 1. Inability to provide written informed consent/assent.
  • 2. Subjects participating in any interventional study or trial for IMISC treatment trial at the time of enrollment. Patients may be enrolled in TARGET-DERM once participation in the trial is complete. Note: Participants may be enrolled in other registries or studies where IMISC treatment outcomes are observed and/or reported (such as center-based registries).

Study Design

Phase
Study Type
Observational [Patient Registry]
Observational Model
Cohort
Time Perspective
Other

Recruiting Locations

The University of Kansas Medical Center
Kansas City, Kansas 66160
Contact:
Caitlin McMillian
913-588-0681
cmcmillian@kumc.edu

More Details

Status
Recruiting
Sponsor
Target PharmaSolutions, Inc.

Study Contact

Laura Dalfonso
9842340268
ldalfonso@targetpharmasolutions.com